Formulation, Optimization, In Vitro and In Vivo Evaluation of Saxagliptin-Loaded Lipospheres for an Improved Pharmacokinetic Behavior

Figure 2

In vitro saxagliptin release (%) with respect of time for F1-F4 (a), F5-F8 (b), F9-F12 (c), and F13-F17 (d).

(a)

(b)

(c)

(d)